Group 1 - Minsheng Health (SZ 301507, closing price: 15.52 CNY) announced on August 19 that its subsidiary, Minsheng Zhongke Jiayi (Shandong) Bioengineering Co., Ltd., received an invention patent certificate from the National Intellectual Property Administration for a strain of Lactobacillus curvatus JYLU-88 that promotes EGF and EGFR expression [2] - For the fiscal year 2024, Minsheng Health's revenue composition is as follows: vitamin and mineral supplements account for 96.91%, other health products for 1.93%, probiotics for 0.66%, other businesses for 0.39%, and therapeutic drugs for 0.11% [2]

Summary of Baia Co., Ltd. Conference Call Company Overview - **Company**: Baia Co., Ltd. - **Industry**: Sanitary products, specifically focusing on women's hygiene products Key Points and Arguments 1. **Recovery in Revenue and Profit**: The most competitive period for online channels has passed, with expectations for revenue and profit to recover, primarily benefiting from L2 strategy optimization and policy restrictions on irrational traffic investments. The months of May and June are seen as clear low points, with July and August showing recovery in GMV on Douyin [2][5] 2. **Dominance of Offline Channels**: Offline channels remain the primary driver for Baia, with the Free Point brand expanding rapidly in peripheral provinces. The first half of the year is expected to see a doubling in growth, and as fixed costs are amortized, profit increases will be non-linear, with key provinces likely to reach profitability inflection points [2][6] 3. **Emergence of Instant Retail**: Baia has positioned itself early in the instant retail space, offering competitive pricing and higher delivery efficiency compared to Douyin. The recovery in e-commerce data combined with strong performance in offline peripheral provinces should be closely monitored for future growth [2][6] 4. **Shift in Growth Strategy**: The company is transitioning from rapid market share growth to enhancing operational quality, leveraging online L2 strategy optimization and new instant retail channels to drive performance growth. The growth cycle of the company is expected to continue [2][7] 5. **Product Strategy and Impact**: In May 2023, Baia launched a probiotic series priced at 1 to 1.2 yuan, which significantly boosted performance and initiated a cycle of large single products. This followed the introduction of a health series in late 2022, which had mixed results due to higher pricing [2][7] 6. **Financial Performance**: Since the second half of 2022, Baia has seen a turning point in performance, with revenue growth of 33% in 2023 and projected 52% in 2024. Despite increased advertising and fixed costs, profit growth remains above 20%. ROE is expected to rise from 15% in 2022 to 20% in 2024, with gross margin increasing from 45% to 53% [4][8] 7. **Regional Market Performance**: Baia holds over 40% market share in the Sichuan-Chongqing region, with stable growth in Yunnan, Guizhou, and Shaanxi. Significant revenue growth is expected in peripheral provinces starting in the second half of 2024, continuing into the first half of 2025 [4][9] 8. **E-commerce and Offline Channel Dynamics**: E-commerce channels have achieved significant results through Douyin and Tmall, but future growth may stabilize at a reasonable range of 20%-30%. The importance of offline channels is increasing, with fixed costs being amortized as scale expands, gradually releasing profit potential [10] 9. **Competitive Advantages**: Baia's local brands, such as Free Point, have stronger offline management capabilities compared to foreign brands, which rely heavily on online channels. The company maintains a close ratio of distributors to sales personnel, enhancing control over terminal sales points and market share [11] 10. **Future Growth Prospects**: As the potential of probiotic products is realized, high-margin products will enhance distributor performance, attracting more distributors. After crossing the breakeven point in various provinces, profit margins are expected to rise rapidly, with projections for continued revenue and profit growth [12]

Core Viewpoint - Minsheng Health announced a share buyback plan, having repurchased approximately 1.33 million shares, representing 0.37% of the total share capital, with a total expenditure of around 17.26 million yuan [2] Summary by Category Share Buyback - As of July 31, 2025, Minsheng Health has repurchased about 1.33 million shares through a special securities account via centralized bidding, with a maximum transaction price of 13.82 yuan per share and a minimum transaction price of 11.83 yuan per share [2] Revenue Composition - For the year 2024, the revenue composition of Minsheng Health is as follows: - Vitamin and mineral supplements account for 96.91% - Other health products account for 1.93% - Probiotics account for 0.66% - Other businesses account for 0.39% - Therapeutic drugs account for 0.11% [2]